^
Association details:
| Biomarker: | EGFR exon 19 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | zorifertinib (AZD3759) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial
Published date:
09/21/2023
Excerpt:
We initiated a phase 2, multi-center, umbrella trial (CTONG1702, NCT03574402). The eighth arm assessed the efficacy and safety of AZD3759 in untreated EGFR-mutated NSCLC with CNS metastases....Based on subgroup analyses, 200 mg bid dose recipients, females, non-smokers, and EGFR exon 19 deletion patients seemed to attain a favourable response to AZD3759 treatment...
DOI:
https://doi.org/10.1016/j.eclinm.2023.102238
Trial ID:
